Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Clinical Research Validates Utility of IVL in Complex Nodular and Eccentric Calcium Clinical Research Validates Utility of IVL in Complex Nodular and Eccentric Calcium

New Shockwave Coronary IVL Publications Confirm Safety and Efficacy Across Multiple Calcium Morphologies

Shockwave Medical, Inc. aims to transform the treatment of calcified cardiovascular disease through intravascular lithotripsy. The company has experienced significant sales growth, with revenues increasing from $12 million in 2018 to $237 million in 2021. Despite a boom-bust cycle in share prices, Shockwave Medical remains profitable and has a strong cash position, making it an attractive investment opportunity.

Shockwave Medical: Interesting Levels Again

SANTA CLARA, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, will host an Investor Innovation Day on Monday, October 23, 2023, from 1:00 p.m to 4:00 p.m. Pacific Time.

Shockwave Medical to Livestream 2023 Investor Innovation Day

Ginkgo Bioworks Holdings

Bio-Techne

Shockwave Medical just got a boost from a Medicare decision on one of its products. Bio-Techne is benefiting from increased cell and gene therapy revenue.

3 Healthcare Stocks to Keep an Eye On

SANTA CLARA, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Nick West, MA, MD, FRCP, FESC, FACC, has joined the company in the role of Associate Chief Medical Officer.

Shockwave Medical Appoints Nick West as Associate Chief Medical Officer

SANTA CLARA, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that Chief Financial Officer Dan Puckett plans to retire in the first quarter of 2024. Dan has served as the CFO at Shockwave since he joined the company in 2016. The Board of Directors has initiated a process to identify a successor. Mr. Puckett plans to continue as the Chief Financial Officer until his successor is appointed.

Shockwave Medical Announces Dan Puckett to Retire as CFO in 2024

Insulet

Transmedics Group Inc

The healthcare sector has underperformed this year, with the Health Care Select Sector SPDR (NYSEARCA: XLV ) down 1%. After a disappointing year-to-date performance, it's time to consider some top healthcare stock picks.

The 3 Most Promising Healthcare Stocks to Own Now

SANTA CLARA, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in two upcoming investor conferences:

Shockwave Medical to Participate in Upcoming Investor Conferences

Duolingo

SoFi Technologies

SoFi Technologies is an all-digital bank with a rapidly growing base of members and deposits. Shockwave Medical makes intravenous lithotripsy devices that reduce the risk of life-threatening complications when cardiovascular surgeons try to open blocked arteries.

A Bull Market Is Coming: 3 Exceptional Growth Stocks to Buy Now and Hold for a Decade

DexCom

Intuitive Surgical

Wegovy and Mounjaro obesity and diabetes drugs are expected to have a significant impact on society and may lead to a decrease in demand for certain medical devices and surgeries. Medical device stocks, such as Shockwave, DexCom, and Intuitive Surgical, have experienced sell-offs due to concerns about the future impact of these drugs. However, there are still millions of overweight and obese individuals who will require medical interventions, creating potential opportunities for these stocks.

The Sell-Off Caused By Wegovy And Mounjaro In Medtech Stocks Offers A Huge Opportunity

SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave Medical”) announced today the pricing of its offering of $650.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The aggregate principal amount of the offering was increased from the previously announced offering size of $500.0 million. Shockwave Medical also granted the initial purchaser of the notes an option to purchase, within a 13-day period from, and including, the date on which the notes are first issued, up to an additional $100.0 million aggregate principal amount of notes. The sale of the notes is expected to close on August 15, 2023, subject to customary closing conditions.

Shockwave Medical Prices Upsized Private Offering of $650.0 Million of 1.00% Convertible Senior Notes Due 2028

SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave Medical”) announced today that it intends to offer, subject to market conditions and other factors, $500.0 million aggregate principal amount of Convertible Senior Notes due 2028 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Shockwave Medical also intends to grant the initial purchaser of the notes an option to purchase, within a 13-day period from, and including, the date on which the notes are first issued, up to an additional $75.0 million aggregate principal amount of notes.

Shockwave Medical Announces Proposed Private Offering of $500.0 Million of Convertible Senior Notes

Shockwave Medical Inc. is a medical device developer focusing on calcified cardiovascular disease treatments, with a promising market opportunity. SWAV recently completed the acquisition of Neovasc Inc., positioning itself to address refractory angina and tap into a large market share. SWAV has strong margins and financial position, but its current valuation is considered overpriced, making it a hold rather than a buy.

Shockwave Medical: Not Worth The Price

Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Shockwave Medical (SWAV) Q2 Earnings Miss, Revenues Surge Y/Y

Shockwave Medical's Q2 results exceeded revenue expectations but fell short on earnings. The bottom-line shortfall came amid acquisition expenses and headcount expansion to support growth.

Why Shockwave Medical Stock Dropped Today

Shockwave Medical, Inc. (NASDAQ:SWAV ) Q2 2023 Earnings Conference Call August 7, 2023 4:30 PM ET Company Participants Debbie Kaster - Vice President, Investor Relations Doug Godshall - President and Chief Executive Officer Isaac Zacharias - President and Chief Commercial Officer Dan Puckett - Chief Financial Officer Robert Fletcher - Senior Vice President, Marketing and Market Access Conference Call Participants William Plavonic - Canaccord Genuity Travis Steed - Bank of America Adam Maeder - Piper Sandler Michael Polark - Wolfe Research Lawrence Biegelsen - Wells Fargo Imron Zafar - Deutsche Bank Mike Matson - Needham & Company Operator Good afternoon and welcome to Shockwave's Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Shockwave Medical, Inc. (SWAV) Q2 2023 Earnings Call Transcript

Shockwave Medical (SWAV) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.68 per share a year ago.

Shockwave Medical (SWAV) Misses Q2 Earnings Estimates

SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023.

Shockwave Medical Reports Second Quarter 2023 Financial Results

Three New IVL-Specific Diagnostic Related Groups (DRGs) with Increased Payments Go Into Effect October 1, 2023 Three New IVL-Specific Diagnostic Related Groups (DRGs) with Increased Payments Go Into Effect October 1, 2023

Centers For Medicare & Medicaid Services Creates New Hospital Inpatient Payment for Coronary Intravascular Lithotripsy

SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Shockwave Medical Announces Details for Conference Call Discussing Second Quarter 2023 Results and Participation in Upcoming Investor Conference

Shockwave Medical received mixed reimbursement news from the Centers for Medicare and Medicaid Services, and SWAV stock tumbled Friday.

Here's The Bad News That Could Keep Shockwave Trapped Under Its 50-Day Line

Medpace Holdings

Healthcare technology stocks can be very lucrative investments. For evidence of that theory, take a look at the performances of three of the top names in the sector since August 2010.

Healthcare Technology: 3 Companies to Keep an Eye On Now

As top money managers scoop up shares in Shockwave Medical, SWAV stock taps sonic waves to clear a path to a buy zone.

Medical Stock With 164% Growth On Track To Crack Breakout Code

Booking Hlds

Marriott

As we enter the final month of the first half of the year, investors' focus is on the next six months and beyond. As a result, you might be on the hunt for the best growth stocks for the second half of 2023.

3 Sizzling Growth Stocks to Buy for 2023's Second Half

SANTA CLARA, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today released its 2022 ESG Report highlighting accomplishments in environmental, social, and governance (ESG) across its global markets.

News for Shockwave Medical Stock (SWAV)